Posted inHematology-Oncology news
Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial
The Phase 3 inMIND trial demonstrates that adding tafasitamab to lenalidomide and rituximab (R2) significantly improves progression-free survival in patients with relapsed or refractory follicular lymphoma, reducing the risk of disease progression or death by 57%.